Related Experiment Videos
Polymorphisms in TP53 and MDM2 combined are associated with high grade endometrial cancer
Katie A Ashton1, Anthony Proietto, Geoffrey Otton
1Discipline of Medical Genetics, School of Biomedical Sciences, Faculty of Health, University of Newcastle, Australia.
Objectives:
Determinants of endometrial cancer grade have not been precisely defined, however, cell cycle control is considered to be integrally involved in endometrial cancer development. TP53 and MDM2 are essential components for cell cycle arrest and apoptosis. Polymorphisms in these genes cause TP53 inactivation and MDM2 over-expression, leading to accumulation of genetic errors.
Methods:
One polymorphism in MDM2, rs2279744 (SNP309) and three polymorphisms in TP53 rs1042522 (R72P), rs17878362 and rs1625895 were genotyped in 191 endometrial cancer cases and 291 controls using PCR-based fragment analysis, RFLP analysis and real-time PCR.
Results:
The results showed no associations of the three TP53 polymorphisms and MDM2 SNP309 alone or in combination with endometrial cancer risk. However, the combination of MDM2 SNP309 and the three TP53 polymorphisms was significantly associated with a higher grade of endometrial cancer (wild-type genotypes versus variant genotypes: OR 4.15, 95% CI 1.82-9.46, p=0.0003). Analysis of family history of breast cancer revealed that the variant genotypes of the three TP53 polymorphisms were significantly related to a higher frequency of family members with breast cancer in comparison to endometrial cancer cases without a family history of breast cancer (wild-type genotypes versus variant genotypes: OR 2.78, 95% CI 1.36-5.67, p=0.004).
Conclusions:
The combination of the MDM2 SNP309 and the three TP53 polymorphisms appear to be related to a higher grade of endometrial cancer. The association of the endometrial cancer cases with family history of breast cancer and the three TP53 polymorphisms suggests that this constellation of malignancies may represent a low-risk familial cancer grouping.
Insights
Genetic variations in TP53 and MDM2 are linked to higher-grade endometrial cancer. This combination of polymorphisms may also indicate a familial cancer grouping, particularly with a history of breast cancer.
Area of Science:
- Oncology
- Genetics
- Cancer Biology
Background:
- Endometrial cancer grade determinants are not fully understood, but cell cycle control is implicated.
- TP53 and MDM2 genes are crucial for cell cycle arrest and apoptosis.
- Polymorphisms in TP53 and MDM2 can lead to TP53 inactivation and MDM2 overexpression, promoting genetic errors.
Purpose of the Study:
- To investigate the association between specific polymorphisms in the TP53 and MDM2 genes and endometrial cancer risk and grade.
- To explore the combined effect of these polymorphisms on endometrial cancer development.
- To examine the relationship between TP53 polymorphisms, family history of breast cancer, and endometrial cancer.
Main Methods:
- Genotyping of one MDM2 polymorphism (rs2279744, SNP309) and three TP53 polymorphisms (rs1042522, rs17878362, rs1625895) was performed.
- The study included 191 endometrial cancer cases and 291 controls.
- Techniques used included PCR-based fragment analysis, RFLP analysis, and real-time PCR.
Main Results:
- No significant association was found between individual TP53 or MDM2 SNP309 polymorphisms and endometrial cancer risk.
- A significant association was observed between the combined genotypes of MDM2 SNP309 and the three TP53 polymorphisms and higher endometrial cancer grade (OR 4.15, p=0.0003).
- Variant TP53 genotypes were significantly related to a higher frequency of family members with breast cancer (OR 2.78, p=0.004).
Conclusions:
- The combination of MDM2 SNP309 and TP53 polymorphisms appears to be associated with increased endometrial cancer grade.
- The observed association between TP53 polymorphisms, endometrial cancer, and a family history of breast cancer suggests a potential low-risk familial cancer grouping.
Related Concept Videos
Abnormal Proliferation
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...